PL1706121T3 - Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (HSEP) do zapobiegania i leczenia zaburzeń neurodegeneracyjnych - Google Patents

Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (HSEP) do zapobiegania i leczenia zaburzeń neurodegeneracyjnych

Info

Publication number
PL1706121T3
PL1706121T3 PL05701469T PL05701469T PL1706121T3 PL 1706121 T3 PL1706121 T3 PL 1706121T3 PL 05701469 T PL05701469 T PL 05701469T PL 05701469 T PL05701469 T PL 05701469T PL 1706121 T3 PL1706121 T3 PL 1706121T3
Authority
PL
Poland
Prior art keywords
endopeptidase
hsep
nep
prophylaxis
treatment
Prior art date
Application number
PL05701469T
Other languages
English (en)
Inventor
Michael Weske
Lechoslaw A Turski
Hrissanthi Ikonomidou
Dieter Ziegler
Original Assignee
Turski Lechoslaw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34796705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1706121(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Turski Lechoslaw filed Critical Turski Lechoslaw
Publication of PL1706121T3 publication Critical patent/PL1706121T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
PL05701469T 2004-01-12 2005-01-10 Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (HSEP) do zapobiegania i leczenia zaburzeń neurodegeneracyjnych PL1706121T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53553804P 2004-01-12 2004-01-12
EP04100067 2004-01-12
EP05701469A EP1706121B1 (en) 2004-01-12 2005-01-10 Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of neurodegenerative disorders
PCT/EP2005/050075 WO2005067937A1 (en) 2004-01-12 2005-01-10 Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
PL1706121T3 true PL1706121T3 (pl) 2009-02-27

Family

ID=34796705

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05701469T PL1706121T3 (pl) 2004-01-12 2005-01-10 Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (HSEP) do zapobiegania i leczenia zaburzeń neurodegeneracyjnych

Country Status (22)

Country Link
EP (1) EP1706121B1 (pl)
JP (1) JP4951350B2 (pl)
KR (1) KR101219580B1 (pl)
CN (1) CN101076339B (pl)
AT (1) ATE406899T1 (pl)
AU (1) AU2005205067B2 (pl)
BR (1) BRPI0506750A (pl)
CA (1) CA2551789C (pl)
CY (1) CY1108588T1 (pl)
DE (1) DE602005009487D1 (pl)
DK (1) DK1706121T3 (pl)
ES (1) ES2313279T3 (pl)
HR (1) HRP20080611T3 (pl)
IL (1) IL176456A (pl)
NO (1) NO20063623L (pl)
PL (1) PL1706121T3 (pl)
PT (1) PT1706121E (pl)
RU (1) RU2362563C2 (pl)
SI (1) SI1706121T1 (pl)
UA (1) UA82008C2 (pl)
WO (1) WO2005067937A1 (pl)
ZA (1) ZA200605549B (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120034193A1 (en) * 2009-01-24 2012-02-09 Daryl Rees Treatment of neurotrophic factor mediated disorders
AR079059A1 (es) 2009-12-07 2011-12-21 Abbott Healthcare Products Bv Acido ((3s)-3-(((1-(((2r)-2-carboxi-4-(1-naftil) butil) ciclopentil)-carbonil) amino )-2-oxo-2,3,4,5-tetrahidro-1h-1-benzazepin-1-il) acetico cristalino, su preparacion y uso
CN106065006B (zh) * 2015-04-22 2020-06-05 深圳信立泰药业股份有限公司 一种中性内肽酶抑制剂盐晶型及其制备方法
PL424453A1 (pl) * 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP)
PL424452A1 (pl) 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
CN110590695B (zh) * 2019-10-22 2023-03-21 南华大学 苯并氮杂环类化合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19750002A1 (de) * 1997-11-12 1999-05-20 Solvay Pharm Gmbh Phosphonsäure-substituierte Benzazepinon-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
JP4350306B2 (ja) * 1998-04-23 2009-10-21 ノバルティス アクチエンゲゼルシャフト エンドセリン変換酵素のチオール型阻害剤
US20020013307A1 (en) * 2000-05-23 2002-01-31 Pablo Lapuerta Use of vasopeptidase inhibitors to treat or slow the progression of cognitive dysfunction and to treat and/or prevent dementia
US6505135B2 (en) * 2001-03-13 2003-01-07 Micro Motion, Inc. Initialization algorithm for drive control in a coriolis flowmeter
AR039352A1 (es) * 2001-05-18 2005-02-16 Solvay Pharm Gmbh Uso de un compuesto que tiene actividad inhibitoria combinada y concurrente con endopeptidasa neutra y metaloproteasa igs5.
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul

Also Published As

Publication number Publication date
BRPI0506750A (pt) 2007-05-22
ATE406899T1 (de) 2008-09-15
DK1706121T3 (da) 2009-01-05
CA2551789A1 (en) 2005-07-28
WO2005067937A1 (en) 2005-07-28
IL176456A (en) 2010-03-28
KR101219580B1 (ko) 2013-01-08
AU2005205067B2 (en) 2009-10-22
RU2362563C2 (ru) 2009-07-27
PT1706121E (pt) 2008-12-04
KR20060123541A (ko) 2006-12-01
DE602005009487D1 (de) 2008-10-16
JP4951350B2 (ja) 2012-06-13
NO20063623L (no) 2006-10-12
JP2007517834A (ja) 2007-07-05
CN101076339A (zh) 2007-11-21
EP1706121A1 (en) 2006-10-04
CA2551789C (en) 2011-05-03
IL176456A0 (en) 2006-10-05
HRP20080611T3 (hr) 2008-12-31
UA82008C2 (uk) 2008-02-25
ES2313279T3 (es) 2009-03-01
SI1706121T1 (sl) 2009-02-28
AU2005205067A1 (en) 2005-07-28
EP1706121B1 (en) 2008-09-03
RU2006129288A (ru) 2008-02-20
CY1108588T1 (el) 2014-04-09
ZA200605549B (en) 2007-12-27
CN101076339B (zh) 2011-02-09

Similar Documents

Publication Publication Date Title
WO2006011050A3 (en) Pyridine derivatives
GEP20125565B (en) Lactam compounds and their pharmaceutical use
HRP20041132A2 (en) 7-aryl-3, 9-diazabicyclo (3.3.1) non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
WO2006099943A8 (de) Amid substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
TW200514772A (en) Novel tetrahydropyridine derivatives
PL1682528T3 (pl) Pochodne benzo[b][1,4]dioksepiny
WO2005040171A8 (en) Pyrazolo and imidazo-pyrimidine derivatives
TW200621716A (en) Novel compounds
GB0420831D0 (en) Novel compounds
CY1108588T1 (el) ΑΝΑΣΤΟΛΕΙΣ ΟΥΔΕΤΕΡΗΣ ΕΝΔΟΠΕΠΤΙΔΑΣΗΣ (ΝΕΡ) ΚΑΙ ΑΝΘΡΩΠΙΝΗΣ ΔΙΑΛΥΤΗΣ ΕΝΔΟΠΕΠΤΙΔΑΣΗΣ (hSEP) ΓΙΑ ΤΗΝ ΠΡΟΦΥΛΑΞΗ ΚΑΙ ΘΕΡΑΠΕΙΑ ΝΕΥΡΟΕΚΦΥΛΙΣΤΙΚΩΝ ΠΑΘΗΣΕΩΝ
EP1725536B8 (en) Imidazoline derivatives having cb1-antagonistic activity
MXPA05011498A (es) Derivados de 9-azabiciclo[3.3.1]non-6-eno con un heteroatomo en la posicion 3 como inhibidores de renina.
WO2005030209A8 (en) Pyridine derivatives and use thereof as urotensin ii antagonists
IL187001A0 (en) Preparation of (s)-4-fluromethyl-dihydro-furan -2-one
MXPA05011496A (es) Derivados de azabiciclononeno.
TW200611701A (en) Novel compounds
WO2007111983A8 (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
TW200637861A (en) Novel diazabicyclononene derivative
GB0407025D0 (en) Novel compounds
TW200621773A (en) Bicyclononene derivatives
WO2007072092A8 (en) New phenanthridine derivatives as bradykinin antagonists
TW200621774A (en) Bicyclononene derivatives
TW200634014A (en) Novel diazabicyclononene derivative